PT-141 Research Guide: Bremelanotide Melanocortin Science

PT-141, known in pharmaceutical development as bremelanotide, is a synthetic cyclic heptapeptide that activates melanocortin receptors in the central nervous system. It occupies an unusual place in peptide research: most compounds of this kind are known only from cell and animal work, whereas PT-141 passed through a full clinical development program — early studies in men, two large phase 3 trials in women, and a 2019 regulatory approval in the United States for one narrowly defined indication. That record makes it a useful case study in how a research peptide becomes — and does not become — a medicine.

This guide reviews what PT-141 is chemically, how melanocortin signaling differs from the peripheral pathways of better-known sexual-medicine drugs, what the human studies found, which safety signals the literature discusses openly, and where the evidence stops — including the line that runs through the whole record: material sold for laboratory research is not the approved drug product.

What Is PT-141?

PT-141 is the development name for bremelanotide, a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Its structure is a seven-amino-acid ring closed by a lactam bridge — a design that protects the active core from rapid enzymatic breakdown and locks it into the shape melanocortin receptors recognize.

• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
• Structure: Cyclic heptapeptide; lactam bridge between the Asp and Lys side chains; D-phenylalanine at the central position
• Molecular formula: C50H68N14O10
• Molecular weight: Approximately 1,025.2 g/mol
• Family: Melanocortin receptor agonist; synthetic alpha-MSH analogue developed from the Melanotan II program
• Development name: Bremelanotide (PT-141)

Three features of that sequence carry most of the pharmacology. The His-D-Phe-Arg-Trp segment is the conserved melanocortin message sequence — the part of alpha-MSH that switches the receptors on. The norleucine (Nle) substitution replaces an oxidation-prone residue. And the ring closure distinguishes this class from native alpha-MSH, which is cleared within minutes.

PT-141 Is Not Melanotan-2

Because the two names appear together so often, the distinction deserves its own short section. Melanotan II is an earlier cyclic melanocortin analogue, developed as a tanning agent and later used in the first human experiments on melanocortin-driven erection and desire. PT-141 was developed from that program and is often described as a metabolite and analogue of Melanotan II: it shares the ring and the core message sequence, but it is a different molecule, with a different C-terminus and its own clinical record. Findings reported for Melanotan II — including its tanning effects — do not transfer automatically to PT-141, and the two should never be treated as interchangeable in a research design. Our separate guide to Melanotan-2 covers that compound on its own terms.

Mechanism: Melanocortin Signaling in the Brain

Melanocortins are peptides cleaved from the precursor proopiomelanocortin. They act on five G-protein-coupled receptors, MC1R through MC5R, each with a different distribution and job: MC1R, on melanocytes, governs pigmentation; MC2R, in the adrenal gland, responds selectively to ACTH; MC3R and MC4R are concentrated in the central nervous system, including hypothalamic circuits involved in energy balance, appetite and sexual function; MC5R appears in exocrine glands and other peripheral tissues. PT-141 is not selective for a single subtype — its sexual-function effects are attributed principally to MC3R and MC4R activity in the brain, as summarized in the compound's foundational review:

Citation: Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. "PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction." Annals of the New York Academy of Sciences. 2003. [PubMed PMID: 12851303]

In that review, systemic administration in rats and nonhuman primates produced erections, and administration in rats activated hypothalamic neurons (increased c-Fos immunoreactivity) — evidence that the effect originates centrally rather than in genital tissue. Preclinical work in female rats pointed the same way, selectively increasing sexual solicitation behavior:

Citation: Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. "Selective Facilitation of Sexual Solicitation in the Female Rat by a Melanocortin Receptor Agonist." Proceedings of the National Academy of Sciences of the United States of America. 2004. [PubMed PMID: 15226502]

Citation: Pfaus J, Giuliano F, Gelez H. "Bremelanotide: An Overview of Preclinical CNS Effects on Female Sexual Function." The Journal of Sexual Medicine. 2007. [PubMed PMID: 17958619]

That central mechanism is the defining contrast with phosphodiesterase type 5 (PDE5) inhibitors. PDE5 drugs act peripherally: they amplify a vascular signal in genital tissue, and require that signal — arousal-driven nitric oxide release — to be present. A melanocortin agonist acts upstream, on the brain circuits that generate desire. That is why the human trials that followed measured desire and distress, not only physical response.

Research History: From Melanotan II to PT-141

The Melanotan II experiments

The human story begins with Melanotan II at the University of Arizona. In a double-blind, placebo-controlled crossover study, Wessells and colleagues reported that it initiated erections in men with psychogenic erectile dysfunction, with nausea, stretching and yawning, and decreased appetite reported more often than after placebo:

Citation: Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. "Synthetic Melanotropic Peptide Initiates Erections in Men With Psychogenic Erectile Dysfunction: Double-Blind, Placebo Controlled Crossover Study." The Journal of Urology. 1998. [PubMed PMID: 9679884]

A follow-up review of the same program, covering psychogenic and organic erectile dysfunction, reported erections without sexual stimulation in most participants and increased desire after a majority of active doses versus placebo — alongside frequent nausea and yawning, including severe nausea in a minority:

Citation: Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. "Melanocortin Receptor Agonists, Penile Erection, and Sexual Motivation: Human Studies With Melanotan II." International Journal of Impotence Research. 2000. [PubMed PMID: 11035391]

Those two results — a central effect on erection and desire, and a tolerability problem dominated by nausea — set the agenda for PT-141: keep the melanocortin activity and find out whether the effect survived in a cleaner compound.

Early PT-141 studies in men

Palatin Technologies developed PT-141 first in men. The intranasal program was evaluated in healthy men and in men with mild-to-moderate erectile dysfunction who responded to a PDE5 inhibitor; erectile responses measured by RigiScan were statistically significant versus placebo above a threshold dose, and flushing and nausea were the most common adverse events:

Citation: Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. "Double-Blind, Placebo-Controlled Evaluation of the Safety, Pharmacokinetic Properties and Pharmacodynamic Effects of Intranasal PT-141, a Melanocortin Receptor Agonist, in Healthy Males and Patients With Mild-to-Moderate Erectile Dysfunction." International Journal of Impotence Research. 2004. [PubMed PMID: 14963471]

The subcutaneous program asked a harder question: whether PT-141 could work in men who reported an inadequate response to sildenafil. In that crossover study, responses at both tested doses were statistically significant, leading the authors to argue that a centrally acting agent might serve a broader patient base than a purely vascular one:

Citation: Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. "Evaluation of the Safety, Pharmacokinetics and Pharmacodynamic Effects of Subcutaneously Administered PT-141, a Melanocortin Receptor Agonist, in Healthy Male Subjects and in Patients With an Inadequate Response to Viagra." International Journal of Impotence Research. 2004. [PubMed PMID: 14999221]

The male indication was not carried to approval. Development pivoted instead toward female sexual desire — where a central, desire-focused mechanism offered something the existing drug landscape did not — and toward the subcutaneous route.

The RECONNECT Program and the 2019 Approval

The pivotal evidence comes from RECONNECT: two identical phase 3, randomized, double-blind, placebo-controlled, multicenter trials (studies 301 and 302) in premenopausal women with hypoactive sexual desire disorder (HSDD). In total, 1,267 women were randomized over 24 weeks. The coprimary endpoints were change in the Female Sexual Function Index desire-domain score and change in a Female Sexual Distress Scale item measuring distress related to low desire. Bremelanotide, evaluated as a subcutaneous product used as needed, produced statistically significant increases in desire and reductions in related distress versus placebo in both studies and in the integrated analysis. Nausea, flushing and headache each occurred in at least 10 percent of treated participants:

Citation: Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstetrics and Gynecology. 2019. [PubMed PMID: 31599840]

Women who completed the double-blind phase could continue into a 52-week open-label extension: of 856 eligible completers, 684 enrolled and 272 finished it. No new safety signals were observed, improvements in desire and distress scores were sustained in the descriptive analyses, and nausea, flushing and headache remained the most common drug-related events:

Citation: Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder." Obstetrics and Gynecology. 2019. [PubMed PMID: 31599847]

On the strength of RECONNECT, the U.S. Food and Drug Administration approved bremelanotide in 2019, marketed as Vyleesi, for premenopausal women with acquired, generalized hypoactive sexual desire disorder. That approval is drug-development history: it applies to a specific manufactured drug product, population and indication. It is not a finding about research-grade material in general.

Safety Signals Discussed in the Literature

The most complete synthesis is the safety review of the entire development program — 43 completed studies and roughly 3,500 subjects, with phase 3 exposure up to 18 months:

Citation: Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. "Safety Profile of Bremelanotide Across the Clinical Development Program." Journal of Women's Health. 2022. [PubMed PMID: 35147466]

• Nausea was the most common adverse event — 40.0 percent on bremelanotide versus 1.3 percent on placebo in the integrated double-blind phase 3 data — and the most common reason for discontinuation. Flushing (20.3 percent), headache (11.3 percent) and injection-site reactions followed.
• Blood pressure: ambulatory monitoring showed small, transient, but statistically significant increases. The authors judged them not clinically important, while advising caution for patients at risk of cardiovascular disease.
• Pigmentation: focal hyperpigmentation was rare when the product was used in accordance with label recommendations, but it occurred in more than one-third of subjects after up to 16 consecutive daily administrations in an earlier study setting. The finding is mechanistically coherent — MC1R activation is the pigmentation pathway — and it is the clearest example here of a signal that appears with frequent, repeated exposure rather than with occasional use as studied in phase 3.

Read together, the common events are tolerability events, mostly mild to moderate, visible from the earliest Melanotan II experiments onward. The signals that require judgment are conditional: blood-pressure effects that matter mainly with cardiovascular risk, and pigmentation that appeared mainly under a frequent-administration pattern the approved product does not use.

What the Evidence Does Not Show

The limits deserve the same plain statement:

• Not approved for men. The early male studies showed activity, but no male indication was approved and the erectile-dysfunction path was not completed to registration.
• Not approved beyond the studied population. The approval covers premenopausal women with acquired, generalized HSDD. The RECONNECT population was 85.6 percent white, 96.6 percent from U.S. sites, with a mean age of 39 — extrapolation beyond it is inference, not evidence.
• Long-term data are bounded. Controlled exposure runs to 24 weeks and total program exposure to 18 months. Effects of longer or more frequent exposure are not characterized — the pigmentation finding under daily administration shows why that gap matters.
• The intranasal record is historical. Intranasal PT-141 was studied early and not carried to an approved product; its data describe an abandoned formulation, not the subcutaneous product that was approved.
• Research material is not the drug product. The approved medicine is a manufactured, quality-controlled drug product with an authorized label. PT-141 sold by NUPEPS is a research-use-only material for laboratory investigation. The clinical literature says nothing about any research supplier's material — its quality can only be established analytically, batch by batch, as the next section covers.

Analytical and Quality Notes

For a cyclic peptide, identity testing has to prove three things: the sequence, the ring, and the absence of the linear precursor. Reversed-phase HPLC establishes purity, resolving the cyclic product from deletion sequences and the uncyclized linear peptide. Mass spectrometry confirms the expected molecular weight of approximately 1,025.2 Da; because cyclization involves loss of water relative to the linear sequence, the observed mass is itself evidence that ring closure occurred. A complete certificate of analysis should report the HPLC chromatogram and purity figure, the observed mass against the expected mass, the salt form as supplied, and identifiers tying the report to the specific batch.

Our guide to reading a peptide COA walks through those checks — chromatogram, observed versus expected mass, and batch specificity — in detail.

Handling and Storage: What Can Actually Be Said

The clinical literature reviewed here does not establish a universal storage regimen for research-grade PT-141, and this guide will not invent one. Peptide stability is formulation-dependent — salt form, lyophilized versus solution state, and exposure to moisture, heat and light all change degradation rates. The responsible position is procedural: treat the batch-specific certificate of analysis and supplier safety documentation for the exact lot in hand as authoritative, record storage conditions in the experimental record, and regard material whose storage history is unknown as analytically uncharacterized — re-verification by HPLC and mass spectrometry is the remedy, not assumption.

Limits and Open Questions

Several questions remain open. The relative contributions of MC3R versus MC4R to the human desire effect are inferred from receptor distribution and animal work, not separated in human experiments — no subtype-selective comparator has been run in people. Durability beyond the open-label extension, and the effect of repeated long-term exposure on pigmentation and blood pressure, are uncharacterized. Whether a centrally acting agent would have succeeded in male erectile dysfunction under a modern trial design is unanswered. And the mechanistic story rests partly on animal models whose translation to human desire — a subjective, questionnaire-measured endpoint — deserves humility: RECONNECT's effect sizes, though statistically significant, were modest increments on those scales.

Conclusion

PT-141 is one of the best-documented compounds in the research-peptide catalog: a defined cyclic heptapeptide, a central mechanism through MC3R and MC4R signaling that contrasts with peripheral PDE5 pharmacology, a two-decade arc from Melanotan II experiments through early studies in men to the RECONNECT phase 3 program, and a 2019 approval for one indication in one population. Its safety record is equally well characterized — dominated by nausea, flushing and headache, with conditional signals on blood pressure and pigmentation that the literature states openly. What that record does not do is extend itself: not to men, not to other populations, not to indefinite use, and not to research-grade material, whose quality stands or falls on its own batch analytics.

Before laboratory use, verify at least 99% purity by HPLC, identity and cyclic structure by mass spectrometry against the expected mass of approximately 1,025.2 Da, and a batch-specific certificate of analysis. NUPEPS supplies PT-141 10MG as a research material, with batch documentation available for review.